Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options

World Journal of Gastroenterology

Volumn 22, Issue 22, 2016, Pages 5285-5292

  Ampuero, Javier ^a,b   Rajender Reddy, K ^c   Romero Gomez, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Daclatasvir; Genotype 3; Hepatitis C; Ledipasvir; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; BMS-790052; IMIDAZOLE DERIVATIVE;

ARTICLE; DISEASE ASSOCIATION; DRUG COMPARISON; DRUG EFFECT; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION; ANTIVIRAL RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; ODDS RATIO; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PROSPECTIVE STUDY; TIME FACTOR; VIROLOGY;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; ODDS RATIO; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS;

EID: 84990303672     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/WJG.V22.I22.5285     Document Type: Article

References (37)

1. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-640 [PMID: 25117132 DOI: 10.1001/jama.2014.7085]
2. Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol 2015; 9: 375-385 [PMID: 25222289 DOI: 10.1586/17474124.2015.960396]
3. Vizuete J, Hubbard H, Lawitz E. Next-Generation Regimens: The Future of Hepatitis C Virus Therapy. Clin Liver Dis 2015; 19: 707-16, vii [PMID: 26466657 DOI: 10.1016/j.cld.2015.06.009]
4. Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 - the new treatment challenge. Aliment Pharmacol Ther 2014; 39: 686-698 [PMID: 24612116]
5. Duseja A, Dhiman RK, Chawla Y, Thumburu KK, Kumar A, Das A, Bhadada S, Bhansali A. Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci 2009; 54: 1778-1782 [PMID: 19513842 DOI: 10.1007/s10620-009-0844-y]
6. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18: 745-759 [PMID: 21992794 DOI: 10.1111/j.1365-2893.2011.01481]
7. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60: 98-105 [PMID: 24615981 DOI: 10.1002/hep.27095]
8. Hézode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: The role of ribavirin. J Hepatol 2016; 64: 215-225 [PMID: 26409316 DOI: 10.1016/j.jhep.2015.09.009]
9. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015; 64: 1824-1833 [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421]
10. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31 [PMID: 16836745]
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560 [PMID: 12958120]
12. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25 [PMID: 14606960]
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PMID: 8721797]
14. Ampuero J, Romero-Gómez M. Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. Gastroenterol Clin North Am 2015; 44: 845-857 [PMID: 26600223 DOI: 10.1016/j.gtc.2015.07.009]
15. Evon DM, Esserman DE, Howell MA, Ruffin RA. Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C. Pharmacopsychiatry 2014; 47: 195-201 [PMID: 25121993 DOI: 10.1055/s-0034-1385929]
16. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20: 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902]
17. Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015; 149: 1462-1470 [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043]
18. Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015; 148: 355-366.e1 [PMID: 25311593 DOI: 10.1053/j.gastro.2014.10.007]
19. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 61: 373-395 [PMID: 24818984 DOI: 10.1016/j.jhep.2014.05.001]
20. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
21. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
22. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-361 [PMID: 25038354 DOI: 10.1001/jama.2014.7734]
23. Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22: 1337-1346 [PMID: 23931586 DOI: 10.1517/13543784.2013.826189]
24. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015; 42: 258-272 [PMID: 26014906 DOI: 10.1111/apt.13264]
25. Laccourreye H, Bonfils P, Brasnu D, Ménard M, Fabre A, Janot F, Bassot V. [Chemotherapy and partial surgery in epithelioma of the pharyngo-larynx]. Ann Otolaryngol Chir Cervicofac 1988; 105: 409-414 [PMID: 2462398 DOI: 10.2147/IDR.S36247]
26. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]
27. Foster GR, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, Agarwal K, HCV Research UK EAP Group. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015; 62: S190-S191
28. Welzel TM, Herzer K, Ferenci P, Petersen J, Gschwantler M, Cornberg M, Berg T, Spengler U, Weiland O, Van der Valk M, Klinker H, Rockstroh J, Ingiliz P, Peck-Radosavljevic M, Jimenez-Exposito MJ, Zeuzem S. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program. J Hepatol 2015; 62: S620
29. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149: 1454-1461.e1 [PMID: 26261007 DOI: 10.1053/j.gastro.2015.07.063]
30. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013; 57: 6333-6340 [PMID: 23877691 DOI: 10.1128/AAC.02193-12]
31. Alqahtani S, Zeuzem S, Manns M, Kuo A, Di Bisceglie AM, Reddy R, Mailliard M, O’Leary J, Pockros P, Kwo PY, Lim JK, Vargas HE, Fried MW, Nelson D, Sulkowski MS. Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study. J Hepatol 2015; 62: S652
32. Chulanov V, Zhdanov K, Kersey K, Zhu Y, Massetto B, Zhuravel S. Sofosbuvir plus ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 infection. Hepatology 2014; 1: 676A
33. Dalgard O, Weis N, Noraberg G, Isaksen K, Oevrehus A, Skalshoj Skjar M, Weiland O. Sofosbuvir containing regimes to patients with HCV genotype 3 infection. A scandinavian real-life experience. J Hepatol 2015; 62: S287
34. Hezode C, Ledinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, Larrey D, Silvain C, Botta-Fridlund D, Leroy V, Bourliere M, D’Alteroche L, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Di Martino V, Carrat F, Fedchuk L, Akremi R, Bennai Y, Bronowicki JP. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015; 62: 314A
35. Ingiliz P, Christensen S, Hueppe D, Lutz T, Schewe K, Boesecke C, Simon KG, Schmutz G, Baumgarten A, Busch H, Maussemail S. German multicenter cohort on sofosbuvir-based treatments in HCV mono- and HIV/HCV co-infected patients (GECOSO). J Hepatol 2015; 62: S650
36. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
37. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]